Rani Therapeutics Holdings (RANI) Liabilities and Shareholders Equity (2020 - 2026)

Rani Therapeutics Holdings' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $51.9 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 115.04% year-over-year to $51.9 million; the TTM figure through Mar 2026 stood at $137.5 million (down 7.09% YoY), while the FY2025 annual figure was $58.6 million, up 60.02% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $51.9 million, down from $58.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $115.3 million in Q1 2022, with the low at $10.1 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $57.9 million (2023), against an average of $63.7 million.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity sank 76.71% in 2025, then soared 115.04% in 2026.
• Rani Therapeutics Holdings' Liabilities and Shareholders Equity stood at $108.0 million in 2022, then tumbled by 46.39% to $57.9 million in 2023, then plunged by 36.75% to $36.6 million in 2024, then surged by 60.02% to $58.6 million in 2025, then decreased by 11.5% to $51.9 million in 2026.
• Business Quant data shows RANI's Liabilities and Shareholders Equity at $51.9 million in Q1 2026, $58.6 million in Q4 2025, and $10.1 million in Q3 2025.